Overview

A Study of LY2216684 and Theophylline in Healthy Subjects

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to confirm that LY2216684 is not an inhibitor of cytochrome P450 1A2 (CYP1A2) in healthy participants using theophylline as a probe substrate for the enzyme. Because LY2216684 has been observed to increase heart rate in some healthy participants, this study will also assess heart rate when coadministered with theophylline.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Phenylethyl Alcohol
Theophylline